DSM-Firmenich elects Ridinger as chair. DSM-Firmenich stock is valued at EUR 26.3 billion

Published on 10/21/2026 at 10:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ridinger replaced Thomas Leysen on October 19, 2026 after the EGM. DSM-Firmenich stock costs EUR 107.90 on October 21, 2026 at a EUR 26.3 billion market value.

Governance and operating metrics

Richard Ridinger became chairman after the October 19, 2026 extraordinary general meeting.
Continuing operations generated EUR 4.664 billion of first-half 2026 revenue and EUR 900 million of adjusted EBITDA.
DSM-Firmenich stock trades at EUR 107.90 at 10:42 a.m. CEST at Lang & Schwarz on October 21, 2026.
Third-quarter sales and revenue are scheduled for November 3, 2026.

Architektur-Render eines gläsernen Forschungsgebäudes nahe Kaiseraugst — dsm-firmenich AG (ISIN CH1216478797) unterhält einen Forschungsstandort nahe Kaiseraugst, hier als modernes Architektur-Render gezeigt, Illustration mit AI erstellt.

DSM-Firmenich (ISIN CH1216478797) was trading at EUR 107.90 at Lang & Schwarz on October 21, 2026 at 10:42 a.m. CEST. dsm-firmenich said on October 19, 2026 that shareholders elected Richard Ridinger as chairman at an extraordinary general meeting. The leadership change gives the stock a fresh governance marker ahead of the next sales update.

Ridinger takes the board chair

Ridinger succeeds Thomas Leysen, who retired from the board. The company said Ridinger had served as an independent director since 2023 and was also elected to the Compensation Committee. The immediate investor question is execution: the board change does not alter the operating figures already guiding the valuation.

The chronology is clear. On August 18, 2026, DSM-Firmenich announced Leysen's retirement and proposed Ridinger as successor, according to MarketScreener. On October 1, 2026, the group completed a EUR 540.00 million share repurchase program, according to MarketScreener. On October 19, 2026, the EGM elected Ridinger as chair, with the official release describing his 2023 board appointment.

What does the chair change mean for execution?

The operating benchmark comes from the first half of 2026. Continuing operations produced EUR 4.664 billion of revenue and EUR 900 million of adjusted EBITDA, equal to a 19.3 percent margin, according to De Belegger. The same report said autonomous revenue growth reached 5.00 percent in the first half and 6.00 percent in the second quarter, while the company maintained an adjusted EBITDA margin target of about 20 percent for 2026. Those figures make cash conversion and portfolio execution more important than the chairmanship alone.

Next reporting date

The next scheduled company date is November 3, 2026, when DSM-Firmenich is listed as due to release third-quarter sales and revenue, according to MarketScreener. That update will test whether the first-half growth rate is carrying into the second half and whether the group can convert its margin target into cash.

Stock value and governance

DSM-Firmenich has a market capitalization of EUR 26.3 billion as of October 21, 2026. The company is listed on Euronext Amsterdam and SIX Swiss Exchange, and it describes its continuing operations as generating more than EUR 9 billion in revenue after the Animal Nutrition and Health divestment.

DSM-Firmenich was trading at EUR 107.90 at Lang & Schwarz on October 21, 2026 at 10:42 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of DSM-Firmenich stock.